… ProQR Announces Presentations at ECFS on Eluforsen for … LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … CFF Research Conference. Presentation at ECFS Conference ProQR will deliver a short talk (ePoster) and a poster …
… ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial … and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research & Development of ProQR, said, “QR-1123 aims to block expression of the toxic …
… ProQR Announces Publication on QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Adamson, Ph.D., senior vice president of ophthalmology for ProQR. “The ongoing clinical trial of QR-110 in patients with …
… ProQR Announces Preclinical Proof of Concept Data for AX-0810 … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Platenburg, Chief Scientific Officer and co-founder, ProQR. “In our AX-0810 program targeting NTCP for cholestatic …
… ProQR Nominates Martin Maier, PhD to Board and Announces … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR to Release Topline Data from Proof of Concept Study of … program,” said Daniel de Boer, Chief Executive Officer of ProQR. “In our pre-clinical models QR-010 showed an … into mid-2018, through some important milestones for ProQR’s development programs that include QR-010 for CF and …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces the Grant of two Key Patents, protecting … QR-010 for Cystic Fibrosis in the US and EU Key Updates ProQR received notice of grant for 2 key patents protecting … General Counsel and Chief Corporate Development Officer of ProQR. “We pursue a very aggressive patent strategy as our 16 …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. …
… ProQR annonce la publication dans Nature Medicine des données … CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société qui … commencer au cours du premier semestre 2019. À propos de ProQRProQR Therapeutics s’efforce de changer les vies grâce …